By Stewart Eisenhart, Emergo Group
The Indian government has begun requesting pricing data from medical device and pharmaceutical product manufacturers in order to more tightly monitor extreme, potentially illegal price variations.
The government’s National Pharmaceutical Pricing Authority (NPPA) has issued letters to some manufacturers of devices regulated under the Indian Drugs & Cosmetics Act requesting current price lists, device specifications and details of any pricing revisions occurring within the past two years.
The NPPA letter specifically mentions cardiac stents, drug eluting stents and orthopedic implants, noting that current laws forbid manufacturers of non-scheduled drugs or devices to increase prices by more than 10% of Maximum Retail Price.
Only manufacturers that have received letters from the NPPA must comply with this request, according to Emergo consultants in Secunderabad.
Stewart Eisenhart covers medical device regulatory affairs for Emergo Group.
